Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.
Department of Medicinal Chemistry, Lexicon Pharmaceuticals, 350 Carter Road, Princeton, New Jersey 08540, USA. ngoodwin@lexpharma.com
Nicole C
NC
Goodwin
Ross
R
Mabon
Bryce A
BA
Harrison
Melanie K
MK
Shadoan
Zheng Y
ZY
Almstead
Yiling
Y
Xie
Jason
J
Healy
Lindsey M
LM
Buhring
Christopher M
CM
DaCosta
Jennifer
J
Bardenhagen
Faika
F
Mseeh
Qingyun
Q
Liu
Amr
A
Nouraldeen
Alan G E
AG
Wilson
S David
SD
Kimball
David R
DR
Powell
David B
DB
Rawlins
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D055808:Drug Discovery; D005947:Glucose / Q000378:metabolism; D006801:Humans; D051379:Mice; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013379:Substrate Specificity; D014994:Xylose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use
D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014994:Xylose; D005947:Glucose